Kodiak Sciences/KOD

$3.06

3.73%
-
1D1W1MYTD1YMAX

About Kodiak Sciences

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Ticker

KOD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Victor Perlroth

Employees

107

Headquarters

Palo alto, United States
Website
kodiak.com

Kodiak Sciences Metrics

BasicAdvanced
$158M
Market cap
-
P/E ratio
-$4.44
EPS
2.40
Beta
-
Dividend rate
$158M
2.40299
$9.80
$1.37
712K
10.119
-43.3%
-73.45%
-47.44%
0.653
0.653
24.88%

What the Analysts think about Kodiak Sciences

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 4 analysts.
14.38% upside
High $5.00
Low $2.00
$3.06
Current price
$3.50
Average price target

Kodiak Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$43M
-27.73%
Profit margin
0%
NaN%

Kodiak Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 23.24%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.53
-$0.95
-$1.13
-$0.82
-
Expected
-$1.14
-$1.21
-$0.77
-$1.07
-$0.87
Surprise
34.05%
-21.3%
46.12%
-23.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Kodiak Sciences stock?

Kodiak Sciences (KOD) has a market cap of $158M as of May 30, 2024.

What is the P/E ratio for Kodiak Sciences stock?

The price to earnings (P/E) ratio for Kodiak Sciences (KOD) stock is 0 as of May 30, 2024.

Does Kodiak Sciences stock pay dividends?

No, Kodiak Sciences (KOD) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Kodiak Sciences dividend payment date?

Kodiak Sciences (KOD) stock does not pay dividends to its shareholders.

What is the beta indicator for Kodiak Sciences?

Kodiak Sciences (KOD) has a beta rating of 2.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Kodiak Sciences stock price target?

The target price for Kodiak Sciences (KOD) stock is $3.5, which is 14.38% above the current price of $3.06. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kodiak Sciences stock

Buy or sell Kodiak Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing